Semantic Scholar search for Glow Stack (BPC-157 + TB-500 + GHK-Cu)SemanticScholarGlow Stack (BPC-157 + TB-500 + GHK-Cu)
Tissue repair micro-cycle (BPC-157 + TB-500 + GHK-Cu)
Protocol overview
Exploratory tissue repair protocol stacking BPC-157, TB-500, and GHK-Cu for soft-tissue and connective-tissue support.
Protocol details
This is a placeholder research protocol. It is not medical advice.
- Focus: musculoskeletal and connective-tissue repair
- Core agents: BPC-157, TB-500, GHK-Cu
- Considerations: human vs animal evidence, dosing ranges, and safety windows must be interpreted from primary literature.
Linked peptides
Peptides that appear in this protocol, with their primary perceived effect profiles.
BPC-157Peptide
Body Protective Compound often discussed for soft-tissue repair, GI support, and inflammation modulation.
TB-500 (Thymosin Beta-4)Peptide
GHK-CuPeptide
Copper-binding tripeptide widely used in skin, hair, and wound-healing contexts, with systemic effects explored in research.
Glow Stack (BPC-157 + TB-500 + GHK-Cu)Peptide
Community tags (where this is used)
Lightweight, anonymous voting on where this protocol tends to show up in people's research (not recommendations or medical guidance).
Community stacks, dosing & cycles
Anonymous, research-framed suggestions for how people structure this protocol in practice. No medical advice; use as inspiration, then cross-check against primary evidence.
| Variant | Stack | Dosage | Cycle | Submitted | Upvotes |
|---|---|---|---|---|---|
Tendon rehab micro-cycle (community-style) Structured around tendon-heavy workloads. PT and sleep/nutrition changes likely contribute significantly. | BPC-157 + TB-500 + GHK-Cu + progressive PT 3x/week | BPC-157 ~250 mcg daily, TB-500 2x/week, GHK-Cu topical nightly | 8–12 weeks with deload weeks as needed | Dec 12, 2025 | |
Tendon rehab micro-cycle (community-style) Structured around tendon-heavy workloads. PT and sleep/nutrition changes likely contribute significantly. | BPC-157 + TB-500 + GHK-Cu + progressive PT 3x/week | BPC-157 ~250 mcg daily, TB-500 2x/week, GHK-Cu topical nightly | 8–12 weeks with deload weeks as needed | Dec 12, 2025 | |
Tendon rehab micro-cycle (community-style) Structured around tendon-heavy workloads. PT and sleep/nutrition changes likely contribute significantly. | BPC-157 + TB-500 + GHK-Cu + progressive PT 3x/week | BPC-157 ~250 mcg daily, TB-500 2x/week, GHK-Cu topical nightly | 8–12 weeks with deload weeks as needed | Dec 12, 2025 | |
Tendon rehab micro-cycle (community-style) Structured around tendon-heavy workloads. PT and sleep/nutrition changes likely contribute significantly. | BPC-157 + TB-500 + GHK-Cu + progressive PT 3x/week | BPC-157 ~250 mcg daily, TB-500 2x/week, GHK-Cu topical nightly | 8–12 weeks with deload weeks as needed | Dec 12, 2025 |
Page 2 of 2
Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential.PubMedTB-500 (Thymosin Beta-4)
Drug testing and analysis · 2012
Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry.PubMedTB-500 (Thymosin Beta-4)
Journal of chromatography. A · 2012
Copper Complexes with New Glycyl-l-histidyl-l-lysine-Hyaluronan Conjugates Show Antioxidant Properties and Osteogenic and Angiogenic Synergistic Effects.PubMedGHK-Cu
Bioconjugate chemistry · 2025
Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms.PubMedGHK-Cu
Frontiers in pharmacology · 2025
An injectable hydroxyapatite microsphere filler loaded with GHK-Cu tripeptide for anti-Inflammatory and antioxidant.PubMedGHK-Cu
Colloids and surfaces. B, Biointerfaces · 2025
Current reviews in musculoskeletal medicine · 2025
BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals 2025, 18, 185.PubMedBPC-157
Pharmaceuticals (Basel, Switzerland) · 2025
Reply to Sikiric et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on "Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals 2025, 18, 185".PubMedBPC-157
Pharmaceuticals (Basel, Switzerland) · 2025